An A1C between 5.7 and 6.4 percent, or a fasting glucose of 100 to 125, puts you in prediabetes, and the first question most people ask is whether there is a pill for it. The short answer: no medicine is approved by the FDA for prediabetes, but two kinds are used. Metformin has been prescribed off label for twenty years and cuts the risk of progressing to diabetes by about a third. The newer GLP-1 medicines, approved for weight, cut it by far more in people who also carry extra weight, but they are not approved for prediabetes on its own and most plans will not pay for them on that basis. This guide explains who the American Diabetes Association says should consider metformin, what the GLP-1 trials showed, what actually reverses prediabetes and how long it takes, and where the gap in options sits for the largest group of all: people who are overweight but not obese.
Prediabetes and a BMI between 25 and 29.9?
A phase 3 study is testing whether orforglipron, the GLP-1 pill in Foundayo, delays type 2 diabetes and other weight-related conditions, or progression to obesity, in adults with a BMI of 25 to 29.9 and prediabetes or borderline blood pressure or cholesterol. Every group receives orforglipron for part of the study. Not open to people with diabetes, or diagnosed high blood pressure or high cholesterol.
Is there a medication for prediabetes?
Not an approved one. The FDA has never approved a drug specifically to treat prediabetes or to prevent type 2 diabetes, so every medicine discussed here is prescribed off label, meaning for a use outside its approval. That is legal and common, but it matters for two reasons: your doctor has to make a judgment call rather than follow a label, and your insurance may decline to pay.
The reason there is no approved medicine is that for most people prediabetes responds to lifestyle change better than to any drug. In the Diabetes Prevention Program, the landmark US trial,a structured program of diet and activity aimed at 7 percent weight loss cut the rate of new diabetes by 58 percent over three years. Metformin in the same trial cut it by 31 percent. That ranking has held up for two decades, which is why the ADA's first recommendation for prediabetes is a prevention program, not a prescription.
Metformin for prediabetes: who should consider it
Metformin is the medicine doctors reach for first, because it is cheap, familiar, and has decades of safety data. The 2026 ADA Standards of Care say it "should be considered" for adults at high risk of type 2 diabetes, and they name the groups where the evidence is strongest: people aged 25 to 59 with a BMI of 35 or higher, people with a fasting glucose of 110 or more, people with an A1C of 6.0 percent or higher, and women who had diabetes during a past pregnancy.
Notice what that list does not include. If you are 60, or your BMI is 28, or your A1C is 5.8, you are in prediabetes, but you are not in the group where metformin has shown the most benefit. The DPP found that metformin worked best in younger people with higher BMIs and showed little benefit in people 60 and older. For many people with mild prediabetes, metformin adds side effects (stomach upset, and with long use a risk of low vitamin B12, which the ADA says to check periodically) for a modest gain.
If your doctor does prescribe it, the dose in the Diabetes Prevention Program was 850 mg twice a day, started low and increased gradually to limit stomach side effects. If you are already on metformin and your numbers are still climbing, our guide covers the signs metformin is not working.
GLP-1 medicines for prediabetes
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are approved for weight management and type 2 diabetes, not for prediabetes. But because they produce large weight loss, and weight is the main driver of prediabetes, they also lower the chance of developing diabetes.
The clearest evidence comes from the SURMOUNT-1 trial of tirzepatide. Among 1,032 adults with obesity and prediabetes who were followed for three years, those on tirzepatide had a 94 percent lower risk of progressing to type 2 diabetes than those on placebo, alongside weight loss of 15 to 23 percent depending on dose. When treatment stopped, some weight came back and some people progressed, which is the catch with the whole class: the protection lasts while you take it.
Three practical limits. These medicines are approved for people with obesity (BMI 30 or higher), or overweight (BMI 27 or higher) with a weight-related condition, and many commercial plans still will not cover them for prediabetes. Medicare is the exception for now: since July 2026, its temporary GLP-1 Bridge covers Wegovy, Zepbound KwikPen, and Foundayo for a $50 monthly copay for people with Part D who have a BMI of 27 or higher and prediabetes, with prior authorization. Without coverage they cost several hundred dollars a month. And most are injections, with nausea in roughly a quarter to nearly half of people, mostly in the first weeks and after dose increases.
Two pills now exist, the Wegovy pill and Foundayo (orforglipron), with the same approval limits; our guide compares Foundayo and Zepbound.
What actually reverses prediabetes
Prediabetes is reversible for many people, and the numbers that move it are weight, activity, and sleep. The ADA's prevention target is losing 5 to 7 percent of body weight and doing at least 150 minutes a week of moderate activity. For someone who weighs 200 pounds, 5 to 7 percent is 10 to 14 pounds. In the DPP, people who reached that target cut their diabetes risk by more than half, and the effect was still visible ten years later.
How long does it take? A1C reflects about three months of blood sugar, so the earliest a change shows fully is a repeat test about three months after you start. Many people see a drop within one to two test cycles if weight is moving.
Our guide to lowering A1C covers what each change is worth in points.
If you have tried and the numbers do not move, that is the moment to talk about medication, and it is also the group that most prediabetes studies are built for.
Borderline diabetes and overweight but not obese: the gap in options
Doctors sometimes say "borderline diabetes" for the same A1C range. Whatever it is called, the people with the fewest options are those with a BMI of 25 to 29.9: overweight, not obese. Their BMI is below the cutoff for most weight loss prescriptions, they are often outside the ADA's metformin groups, and they are usually told to lose weight with diet and exercise they have already tried.
This is the group one large clinical study is built for. A phase 3 study of orforglipron, the medicine in Foundayo, is enrolling adults with a BMI of 25 to 29.9 whose waist measures at least half their height, who have at least one early warning sign such as prediabetes, borderline high blood pressure, or borderline cholesterol, and who have tried at least once to lose weight with diet and exercise. The question it asks is whether a daily GLP-1 pill at this earlier stage delays type 2 diabetes and other weight-related conditions, or progression to obesity, over two years. Orforglipron is approved under the name Foundayo for obesity, or overweight with a weight-related condition; its use in this group is investigational. People who already have diabetes, a diagnosis of high blood pressure or high cholesterol, a BMI of 30 or higher now or in the past, or a weight loss medicine in the past six months are not eligible.
Every group receives orforglipron for part of the study, and some participants also receive a placebo for part of the time; our guide explains how placebo-controlled trials work.
If your BMI is 30 or higher, a group of weight loss studies for adults with overweight or obesity is enrolling, with or without prediabetes, and our diabetes clinical trials page lists prediabetes and prevention studies by city and state.
How to decide
A reasonable order, which matches how the ADA lays it out: a structured prevention program first, or at least a concrete weight and activity target with a repeat A1C in three months. Metformin if you are in one of the high-benefit groups, or if lifestyle change has not moved the numbers after a fair try. A GLP-1 medicine if you have obesity or a qualifying weight-related condition and can access it. And a clinical study if you fall in the gap, especially the BMI 25 to 29.9 range where no approved option fits.
Applying to a study takes about five minutes: you answer questions about your weight, your blood tests, and any medicines you take, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and you can leave at any time.
Common questions
Is there an FDA-approved medication for prediabetes? No. Metformin and GLP-1 medicines are prescribed for prediabetes off label. The FDA has not approved any drug specifically to treat prediabetes or prevent type 2 diabetes.
Should I take metformin for prediabetes? The ADA says to consider it if you are 25 to 59 with a BMI of 35 or higher, have a fasting glucose of 110 or more, an A1C of 6.0 percent or higher, or had gestational diabetes. Outside those groups the benefit is smaller, and it is a decision for you and your doctor.
Does Ozempic or Zepbound treat prediabetes? They are not approved for it, but in people with obesity they prevent diabetes as a result of weight loss. In a three-year trial, tirzepatide lowered the risk of progressing to type 2 diabetes by 94 percent in adults with obesity and prediabetes.
How long does it take to reverse prediabetes? A1C reflects about three months of blood sugar, so expect to see the full effect of a change at a repeat test three months later. Losing 5 to 7 percent of body weight is the target the ADA sets, and many people reach a normal A1C within one to two test cycles.
What is borderline diabetes? Another name for prediabetes: an A1C of 5.7 to 6.4 percent or a fasting glucose of 100 to 125 mg/dL. It is not diabetes, but without changes, many people with prediabetes develop type 2 diabetes within five years.
Can I join a prediabetes study if I am overweight but not obese? Yes. A phase 3 study of orforglipron enrolls adults with a BMI of 25 to 29.9 who have prediabetes or borderline blood pressure or cholesterol and do not have diabetes.
Do prediabetes trial participants get paid? Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
